000186485 001__ 186485
000186485 005__ 20241220120852.0
000186485 0247_ $$2doi$$a10.1002/ijc.34416
000186485 0247_ $$2pmid$$apmid:36571455
000186485 0247_ $$2ISSN$$a0020-7136
000186485 0247_ $$2ISSN$$a1097-0215
000186485 0247_ $$2altmetric$$aaltmetric:140600328
000186485 037__ $$aDKFZ-2022-03206
000186485 041__ $$aEnglish
000186485 082__ $$a610
000186485 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000186485 245__ $$aLong-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
000186485 260__ $$aBognor Regis$$bWiley-Liss$$c2023
000186485 3367_ $$2DRIVER$$aarticle
000186485 3367_ $$2DataCite$$aOutput Types/Journal article
000186485 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1678881980_29492
000186485 3367_ $$2BibTeX$$aARTICLE
000186485 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186485 3367_ $$00$$2EndNote$$aJournal Article
000186485 500__ $$a#EA:C020# / 2023 May 1;152(9):1837-1846
000186485 520__ $$aSurvival studies are an important indicator of the success of cancer control. We analyzed the 5-year relative survival in 23 solid cancers in Denmark, Finland, Norway and Sweden over a 50-year period (1970-2019) at the NORDCAN database accessed from the International Agency for Research on Cancer website. We plotted survival curves in 5-year periods and showed 5-year periodic survival. The survival results were summarized in 4 groups: 1) cancers with historically good survival (>50% in 1970-74) which include melanoma and breast, endometrial and thyroid cancers; 2) cancers which constantly improved survival at least 20 % units over the 50 year period, including cancers of the stomach, colon, rectum, kidney, brain and ovary; 3) cancer with increase in survival >20 % units with changes taking place in a narrow time window, including oral, oropharyngeal, testicular and prostate cancers; 4) the remaining cancers with <20 % unit improvement in survival including lung, esophageal, liver, pancreatic, bladder, soft tissue, penile, cervical and vulvar cancers. For cancers in groups 1 and 2, the constant development implied multiple improvements in therapy, diagnosis and patient care. Cancers in group 3 included testicular cancers with known therapeutic improvements but for the others large incidence changes probably implied that cancer stage (prostate) or etiology (oropharynx) changed into a more tractable form. Group 4 cancers included those with dismal survival 50 years ago but a clear tendency upwards. In 17 cancers 5-year survival reached between 50 and 100 % while in only 6 cancers it remained at below 50%. This article is protected by copyright. All rights reserved.
000186485 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000186485 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186485 650_7 $$2Other$$aearly diagnosis
000186485 650_7 $$2Other$$aperiodic survival
000186485 650_7 $$2Other$$aprognosis
000186485 650_7 $$2Other$$arelative survival
000186485 650_7 $$2Other$$atreatment
000186485 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000186485 7001_ $$aLiska, Vaclav$$b2
000186485 7001_ $$aKanerva, Anna$$b3
000186485 7001_ $$aHemminki, Otto$$b4
000186485 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b5
000186485 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34416$$gp. ijc.34416$$n9$$p1837-1846$$tInternational journal of cancer$$v152$$x0020-7136$$y2023
000186485 8767_ $$82022 (V10366)$$92022-06-23$$d2024-12-19$$eHybrid-OA$$jZahlung erfolgt
000186485 909CO $$ooai:inrepo02.dkfz.de:186485$$pVDB$$pOpenAPC$$popenCost
000186485 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186485 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000186485 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000186485 9141_ $$y2022
000186485 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-25$$wger
000186485 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000186485 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000186485 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000186485 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000186485 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000186485 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000186485 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000186485 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000186485 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000186485 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000186485 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000186485 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000186485 980__ $$ajournal
000186485 980__ $$aVDB
000186485 980__ $$aI:(DE-He78)C020-20160331
000186485 980__ $$aI:(DE-He78)B062-20160331
000186485 980__ $$aI:(DE-He78)HD01-20160331
000186485 980__ $$aUNRESTRICTED
000186485 980__ $$aAPC